Article

Cancers modulate p53 truncal neoantigen display to evade T cell detection

2025-11-30

Abstract excerpt

<h4>Summary paragraph</h4> TP53 mutations are early truncal events across cancers 1,2 . These are perceived to encode tumour-specific neoantigens representing prime cytotoxic T lymphocyte (CTL) targets 3,4 . However, studies systematically examining the physical cell surface display of p53 peptides bound to major histocompatibility complex molecules (pMHC), their relative antigenicity, and resultant immunogenic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 21947109-26e0-552a-b0b5-9a9c8a32fd0d
DOI: 10.1101/2025.11.26.690562

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cancers modulate p53 truncal neoantigen display to evade T cell detectionDOI 10.1101/2025.11.26.690562Read

Proteogenomic analysis unveils the HLA Class I presented immunopeptidome in melanoma and EGFR mutant lung adenocarcinomaSemantic proximity Read

Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapySemantic proximity Read

Discovery of prevalent, clinically actionable tumor neoepitopes via integrated biochemical and cell-based platformsSemantic proximity Read

Proteogenomic analysis reveals RNA as an important source for tumor-agnostic neoantigen identification correlating with T-cell infiltrationSemantic proximity Read

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identificationSemantic proximity Read

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read

Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.Semantic proximity Read

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.Semantic proximity Read

Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discoverySemantic proximity Read

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA allelesSemantic proximity Read

From prediction to precision: how immunopeptidomics advances neoantigen discovery.Semantic proximity Read

ImmuniT Platform for Improved Neoantigen Prediction in Lung CancerSemantic proximity Read